Download PDF
Aktuelle Neurologie 2013; 40(02): 101-103
DOI: 10.1055/s-0032-1332945
Aktuelle Therapie
© Georg Thieme Verlag KG Stuttgart · New York

Kritischer Kommentar zu den „Empfehlungen zum Einsatz der neuen Antikoagulanzien Dabigatran (Pradaxa®) und Rivaroxaban (Xarelto®)“ der Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ)

Gemeinsame Stellungnahme der Deutschen Gesellschaft für Neurologie (DGN) und der Deutschen Schlaganfall-Gesellschaft (DSG)Comments Concerning the “Recommendations fot the Use of the Novel Anticoagulants Dabigatran and Rivaroxaban” Provided by the AkdÄJoint Statement of the German Society of Neurology (DGN) and the German Stroke Society (DSG)
H. C. Diener
1   Klinik für Neurologie am Universitätsklinikum Essen für die Deutsche Gesellschaft für Neurologie (DGN) und die Deutsche Schlaganfall-Gesellschaft (DSG)
,
S. H. Hohnloser
2   Med. Klinik III, Kardiologie, Johann Wolfgang Goethe-Universität in Frankfurt am Main
› Author Affiliations
Further Information

Publication History

Publication Date:
18 February 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Vorhofflimmern - Schlaganfall - neue Antikoagulanzien

Keywords

atrial fibrillation - stroke - novel anticoagulants
 

  • Literatur

  • 1 Guyatt GH et al. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based clinical practice guidelines. Chest 2012; 141: 7S-47S
    CrossrefPubMedGoogle Scholar
  • 2 Camm A, Lip G, De Caterina R et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation. Europ Heart J 2012; 33: 2719-2747
    CrossrefPubMedGoogle Scholar
  • 3 Endres M, Diener HC, Röther J. Sekundärprophylaxe des ischämischen Insults. In: Diener HC, Weimar C, Berlit P, Deuschl G, Elger C, Gold R, Hacke W, Hufschmidt A, Mattle H, Meier U, Oertel WH, Reichmann H, Schmutzhard E, Wallesch C-W, Weller M, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. 5.. Aufl. Stuttgart: Thieme; 2012: 324-347
    Google Scholar
  • 4 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867
    CrossrefPubMedGoogle Scholar
  • 5 Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
    CrossrefPubMedGoogle Scholar
  • 6 Patel MR, Mahaffey KW, Garg J. ROCKET AF Investigators et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
    CrossrefPubMedGoogle Scholar
  • 7 Hart RG, Diener HC, Yang S et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 43: 1511-1517
    CrossrefPubMedGoogle Scholar
  • 8 Haeusler KG, Konieczny M, Endres M et al. Impact of anticoagulation before stroke on stroke severity and long-term survival. Int J Stroke 2011; 7: 544-550
    PubMedGoogle Scholar
  • 9 Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372
    CrossrefPubMedGoogle Scholar